Clinical trial

A Study of Tobemstomig Plus Platinum-Based Chemotherapy vs Pembrolizumab Plus Platinum-Based Chemotherapy in Participants With Previously Untreated Non-Small Cell Lung Cancer

NCT05775289

Drugs and interventions used in this trial

5 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

Search this trial's interventions

DRUG · Unmapped registry intervention Tobemstomig Find medicine records · Find other trials using this name

DRUG · Mapped RxNorm record Pembrolizumab Normalized identity: pembrolizumabView linked drug · Find medicine records · Find other trials using this name

DRUG · Mapped RxNorm record Paclitaxel Normalized identity: paclitaxelView linked drug · Find medicine records · Find other trials using this name

DRUG · Mapped RxNorm record Pemetrexed Normalized identity: pemetrexedView linked drug · Find medicine records · Find other trials using this name

DRUG · Mapped RxNorm record Carboplatin Normalized identity: carboplatinView linked drug · Find medicine records · Find other trials using this name

Study at a glance

Registry-backed

A Study of Tobemstomig Plus Platinum-Based Chemotherapy vs Pembrolizumab Plus Platinum-Based Chemotherapy in Participants With Previously Untreated Non-Small Cell Lung Cancer

Design: INTERVENTIONAL · Status: COMPLETED · Phase: PHASE2

Read study objectives, eligibility and outcome measures at ClinicalTrials.gov

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2023-03-15

PhasePHASE2

Conditions

Non-small Cell Lung Cancerverified · MONDO: non-small cell lung carcinoma

Interventions

TobemstomigDRUG

PembrolizumabDRUG · verified · RxNorm: pembrolizumab

PaclitaxelDRUG · verified · RxNorm: paclitaxel

PemetrexedDRUG · verified · RxNorm: pemetrexed

CarboplatinDRUG · verified · RxNorm: carboplatin

Sponsors & collaborators

Hoffmann-La Rochelead sponsor

Mapped research locations

SeoulSouth Korea3 AnkaraTurkey (Türkiye)2 Porto AlegreRio Grande do Sul, Brazil2 MadridSpain1 BarcelonaSpain1 ParisFrance1 DetroitMichigan, United States1 ToulouseFrance1 BrusselsBelgium1 LyonFrance1 IstanbulTurkey (Türkiye)1 LeuvenBelgium1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT05775289 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.